Biohacking Investment Accounting

Biohacking Investment Accounting: Measurement and Reporting of

Investments in Biotechnology and Body Modification

Introduction

Biohacking refers to the controversial practice of conducting experiments on one's own body

in an attempt to enhance or augment human abilities and functions. This includes implanting

technology under the skin or modifying DNA, nerve cells and tissues at a microscopic level.

While still in its infancy, interest in biohacking is growing among some scientists,

entrepreneurs and ordinary people seeking "self-improvement." This has spurred investment

from venture capital funds looking to tap into emerging biotechnology opportunities.

There are a few common models emerging where for-profit capital is being allocated towards

biohacking-enabling goals:

- Biotechnology startups conducting R&D into areas like nootropics, brain-computer

interfaces, genetic engineering and synthetic biology for potential medical or enhancement

applications. Early investment goes towards lab equipment, prototype development and

clinical trials.

- Wearable device/app companies developing products allowing tracking and optimization of

bodily metrics like sleep, activity levels, brainwaves etc. Many also explore closed-loop

systems offering real-time biofeedback. Seed funding supports software/hardware

engineering.

- Peer-to-peer investment platforms allow individuals to crowdfund or invest in projects

focused on anti-aging, nootropic formulations, brain computer interfaces and other biohack-

enabling inventions and scientific pursuits.

The dilemma for investors and accountants lies in dealing with the high uncertainty and low

probabilities of success characteristic of cutting-edge science, presence of unproven concepts

rather than productized innovations and ethical/legal risks associated with human bodily

experimentation.

Accounting Recognition and Measurement

There is little authoritative accounting guidance covering investments in speculative frontier

sci-tech ventures or human experimentation. Judgement is required to determine appropriate

- Costs contributing to identifiable assets meeting capitalization criteria could potentially be

recognized as intangible development assets if technical/commercial feasibility can be

reasonably demonstrated. High threshold given uncertainties.

Equity Instruments

- Investments in biohacking startups taking form of preferred shares or common stock would

likely be classified as investments in associates (IAS 28) or equity securities (FASB 321)

depending on level of influence.

- Recognition is at fair value with changes through profit and loss unless ownership level

allows use of equity method reporting share of associate net assets/profits. Valuation is highly

subjective given early stage.

evidence procedures satisfy local laws/ethics standards.

Impairment Testing

- For recognized intangibles and equity investments, significant doubt exists over ability to

generate sufficient cash flows to recover carrying amounts due to technology/market risks.

- Impairment assessments require highly subjective assumptions for determining recoverable

amounts using value-in-use or fair value less costs of disposal methods. Sensitivities should

be disclosed.

Disclosure Requirements

- Thorough qualitative disclosures on judgements applied, uncertainties, risk factors and

sensitivity of measurements to assumptions is critical given volatility and lack of precedents

in financial reporting of biohacking endeavors.

experimentation from an accounting perspective. Significant subjectivity is inevitable.

Long Development Cycles:

- Timelines to progress concepts/inventions to marketability are extended due to complex

scientific, regulatory and ethical hurdles. This increases uncertainty in cash flow projections

for impairment tests and asset valuations.

Intangible Asset Identification:

- Delineating research costs from identifiable intangible development assets meeting

capitalization criteria is difficult due to blurred lines between investigation and applied

development phases when technologies are radical and unproven.

Ever-Changing Goals and Risks:

- Objectives of biohacking projects can shift substantially over time in response to R&D

results or emerging opportunities, increasing measurement subjectivity. Technical and non-

technical risks are also hard to foresee and may be underestimated.

scientifically/legally possible.

- Effects of laws, regulator actions, shifts in social acceptance levels on probability of success

legal/ethical grey areas.

Information Asymmetry:

- Limited disclosure of detailed methodologies, data and outcome metrics by private

biohacking outfits further hinders independent verification/scrutiny of reported values and

assumptions by financial statement users.

While applying standard accounting frameworks, the above complexities introduce

considerable measurement subjectivity, uncertainties and audit risks. Conservative

approaches and robust disclosure are advisable in circumstances lacking precedents and

controls.

ventures include:

equity instruments at fair value through profit or loss under IFRS 9/FASB 321 given lack of

control.

Initial Recognition:

characteristics absent active markets.

Subsequent Measurement:

- Use basic valuation techniques like option pricing or recent transaction benchmarks with

Impairment Testing:

- Compare carrying amount to value in use estimated using DCF of projected cash flows.

Incorporate high discount rates and scenario analysis reflecting technology and market

used and their inherent limitations/sensitivities due to early stage nature.

of numerical valuations for high-risk investments lacking precedents or reliable forecasts.

Conclusion

known and legally/ethically permissible. Existing accounting frameworks provide little

definitive guidance requiring management to apply careful judgement. However, failure to

recognize such activities could misrepresent an entity's financial position and economic

exposure to emerging opportunities.

This paper has proposed high-level frameworks for classifying costs, recognizing and

measuring investments in biohacking according to basic IFRS/GAAP concepts. It emphasizes

robust qualitative disclosure to convey substantial uncertainties inherent in attempting to

apply numerical valuations to high-risk sci-tech endeavors lacking data benchmarks.

As the fields of biotechnology, genetics, synthetic biology, brain-computer interfaces, human

speculative ventures at the frontier of science, law and ethics.

Biohacking refers to the controversial practice of conducting experiments on one's own body

technology under the skin or modifying DNA, nerve cells and tissues at a microscopic level.

While still in its infancy, interest in biohacking is growing among some scientists,

entrepreneurs and ordinary people seeking "self-improvement." This has spurred investment

from venture capital funds looking to tap into emerging biotechnology opportunities.

experimental nature of the science as well as ethical and legal uncertainties. This paper will

examine the issues surrounding the appropriate financial reporting of money invested in

biohacking-related ventures, research and body modification procedures from an accounting

perspective.

applications. Early investment goes towards lab equipment, prototype development and

- Wearable device/app companies developing products allowing tracking and optimization of

bodily metrics like sleep, activity levels, brainwaves etc. Many also explore closed-loop

- DIY bio labs and "bioart collectives" where member subscriptions and donations finance

open-source projects in fields such as regenerative medicine, genetic engineering and

microbiome modification. Goals are knowledge sharing rather than commercialization.

- Underground body modification facilities performing procedures like microchipping,

magnet implants and augmented reality contact lenses for a fee. Operate in legal grey areas

facing regulatory risks.

enabling inventions and scientific pursuits.

experimentation.

Accounting Recognition and Measurement

sci-tech ventures or human experimentation. Judgement is required to determine appropriate

classification, timing of recognition and measurement approaches. Some considerations

include:

- Expenses incurred towards open-ended investigation of concepts and ideas without definite

commercial potential would qualify as research costs expensed under IAS 38 and FASB

standards.

Equity Instruments

depending on level of influence.

- Recognition is at fair value with changes through profit and loss unless ownership level

allows use of equity method reporting share of associate net assets/profits. Valuation is highly

subjective given early stage.

- Payments towards human experimentation procedures pose complex measurement issues.

Recording as intangible assets on balance sheet could constitute endorsement of unregulated

medical practice.

- Treatment as R&D or general marketing/sales costs may be most reasonable classification

absent assets arising despite outcomes highly uncertain. Any asset recognition requires

evidence procedures satisfy local laws/ethics standards.

Impairment Testing

Disclosure Requirements

- Thorough qualitative disclosures on judgements applied, uncertainties, risk factors and

sensitivity of measurements to assumptions is critical given volatility and lack of precedents

in financial reporting of biohacking endeavors.

The proposed framework aims to balance principles of faithful representation while

highlighting limitations of numerical values attributed to such frontier ventures and human

experimentation from an accounting perspective. Significant subjectivity is inevitable.

Some special challenges in reporting on biohacking ventures include:

Long Development Cycles:

- Timelines to progress concepts/inventions to marketability are extended due to complex

- Delineating research costs from identifiable intangible development assets meeting

- Objectives of biohacking projects can shift substantially over time in response to R&D

results or emerging opportunities, increasing measurement subjectivity. Technical and non-

technical risks are also hard to foresee and may be underestimated.

- Absence of transaction evidence, industry standards or regulatory clarity for valuation

benchmarks regarding technologies, procedures or business models at the frontier of what is

scientifically/legally possible.

Ethical and Legal Risks:

- Effects of laws, regulator actions, shifts in social acceptance levels on probability of success

assumptions are extremely hard to reliably forecast for ventures/experimentation operating in

legal/ethical grey areas.

biohacking outfits further hinders independent verification/scrutiny of reported values and

approaches and robust disclosure are advisable in circumstances lacking precedents and

controls.

Accounting for Equity Investments in Biohacking

ventures include:

Classification:

equity instruments at fair value through profit or loss under IFRS 9/FASB 321 given lack of

control.

Initial Recognition:

- Use basic valuation techniques like option pricing or recent transaction benchmarks with

Impairment Testing:

Incorporate high discount rates and scenario analysis reflecting technology and market

development uncertainty.

- Provide robust explanations of judgements, valuation methodologies applied, assumptions

used and their inherent limitations/sensitivities due to early stage nature.

The objective is to apply principles of neutrality, prudence and transparency given limitations

of numerical valuations for high-risk investments lacking precedents or reliable forecasts.

Comparative treatment year-over-year is also important for financial analysis.

Conclusion

known and legally/ethically permissible. Existing accounting frameworks provide little

This paper has proposed high-level frameworks for classifying costs, recognizing and

measuring investments in biohacking according to basic IFRS/GAAP concepts. It emphasizes

robust qualitative disclosure to convey substantial uncertainties inherent in attempting to

apply numerical valuations to high-risk sci-tech endeavors lacking data benchmarks.

As the fields of biotechnology, genetics, synthetic biology, brain-computer interfaces, human

augmentation and regenerative medicine progress over time in terms of scientific milestones,

commercial viability and ethical/regulatory acceptance levels, more precedents will emerge

conservatism and transparency are advisable when dealing with the financial reporting of

speculative ventures at the frontier of science, law and ethics.

entrepreneurs and ordinary people seeking "self-improvement." This has spurred investment

experimental nature of the science as well as ethical and legal uncertainties. This paper will

biohacking-related ventures, research and body modification procedures from an accounting

perspective.

- Thorough qualitative disclosures on judgements applied, uncertainties, risk factors and

sensitivity of measurements to assumptions is critical given volatility and lack of precedents

in financial reporting of biohacking endeavors.

The proposed framework aims to balance principles of faithful representation while

highlighting limitations of numerical values attributed to such frontier ventures and human

experimentation from an accounting perspective. Significant subjectivity is inevitable.

Accounting Challenges in Biohacking Investments

Long Development Cycles:

Intangible Asset Identification:

- Delineating research costs from identifiable intangible development assets meeting

capitalization criteria is difficult due to blurred lines between investigation and applied

development phases when technologies are radical and unproven.

Ever-Changing Goals and Risks:

- Objectives of biohacking projects can shift substantially over time in response to R&D

results or emerging opportunities, increasing measurement subjectivity. Technical and non-

technical risks are also hard to foresee and may be underestimated.

Lack of Precedents and Comparables:

- Absence of transaction evidence, industry standards or regulatory clarity for valuation

benchmarks regarding technologies, procedures or business models at the frontier of what is

scientifically/legally possible.

legal/ethical grey areas.

- Limited disclosure of detailed methodologies, data and outcome metrics by private

assumptions by financial statement users.

While applying standard accounting frameworks, the above complexities introduce

approaches and robust disclosure are advisable in circumstances lacking precedents and

controls.

Accounting for Equity Investments in Biohacking

Some practical guidelines for accounting for equity investments in speculative biohacking

ventures include:

Classification:

control.

Subsequent Measurement:

- Use basic valuation techniques like option pricing or recent transaction benchmarks with

suitable discounting for lack of comparables/liquidity.

Impairment Testing:

- Compare carrying amount to value in use estimated using DCF of projected cash flows.

Incorporate high discount rates and scenario analysis reflecting technology and market

development uncertainty.

Disclosures:

- Provide robust explanations of judgements, valuation methodologies applied, assumptions

used and their inherent limitations/sensitivities due to early stage nature.

Conclusion

presents challenges due to technologies being at the outer frontiers of what is scientifically

definitive guidance requiring management to apply careful judgement. However, failure to

recognize such activities could misrepresent an entity's financial position and economic

exposure to emerging opportunities.

This paper has proposed high-level frameworks for classifying costs, recognizing and

measuring investments in biohacking according to basic IFRS/GAAP concepts. It emphasizes

robust qualitative disclosure to convey substantial uncertainties inherent in attempting to

apply numerical valuations to high-risk sci-tech endeavors lacking data benchmarks.

Independent verification is also difficult given information asymmetries.

As the fields of biotechnology, genetics, synthetic biology, brain-computer interfaces, human

augmentation and regenerative medicine progress over time in terms of scientific milestones,

commercial viability and ethical/regulatory acceptance levels, more precedents will emerge

speculative ventures at the frontier of science, law and ethics.

technology under the skin or modifying DNA, nerve cells and tissues at a microscopic level.

While still in its infancy, interest in biohacking is growing among some scientists,

entrepreneurs and ordinary people seeking "self-improvement." This has spurred investment

from venture capital funds looking to tap into emerging biotechnology opportunities.

experimental nature of the science as well as ethical and legal uncertainties. This paper will

examine the issues surrounding the appropriate financial reporting of money invested in

biohacking-related ventures, research and body modification procedures from an accounting

perspective.

Biohacking Business Models and Investments

There are a few common models emerging where for-profit capital is being allocated towards

biohacking-enabling goals:

systems offering real-time biofeedback. Seed funding supports software/hardware

- DIY bio labs and "bioart collectives" where member subscriptions and donations finance

open-source projects in fields such as regenerative medicine, genetic engineering and

- Underground body modification facilities performing procedures like microchipping,

magnet implants and augmented reality contact lenses for a fee. Operate in legal grey areas

facing regulatory risks.

- Peer-to-peer investment platforms allow individuals to crowdfund or invest in projects

focused on anti-aging, nootropic formulations, brain computer interfaces and other biohack-

enabling inventions and scientific pursuits.

The dilemma for investors and accountants lies in dealing with the high uncertainty and low

experimentation.

sci-tech ventures or human experimentation. Judgement is required to determine appropriate

classification, timing of recognition and measurement approaches. Some considerations

include:

- Expenses incurred towards open-ended investigation of concepts and ideas without definite

commercial potential would qualify as research costs expensed under IAS 38 and FASB

standards.

recognized as intangible development assets if technical/commercial feasibility can be

reasonably demonstrated. High threshold given uncertainties.

Equity Instruments

- Recognition is at fair value with changes through profit and loss unless ownership level

- Payments towards human experimentation procedures pose complex measurement issues.

Recording as intangible assets on balance sheet could constitute endorsement of unregulated

medical practice.

- Treatment as R&D or general marketing/sales costs may be most reasonable classification

absent assets arising despite outcomes highly uncertain. Any asset recognition requires

evidence procedures satisfy local laws/ethics standards.

Impairment Testing

- For recognized intangibles and equity investments, significant doubt exists over ability to

generate sufficient cash flows to recover carrying amounts due to technology/market risks.

- Impairment assessments require highly subjective assumptions for determining recoverable

The proposed framework aims to balance principles of faithful representation while

highlighting limitations of numerical values attributed to such frontier ventures and human

experimentation from an accounting perspective. Significant subjectivity is inevitable.

Accounting Challenges in Biohacking Investments

Some special challenges in reporting on biohacking ventures include:

Long Development Cycles:

scientific, regulatory and ethical hurdles. This increases uncertainty in cash flow projections

for impairment tests and asset valuations.

Intangible Asset Identification:

Ever-Changing Goals and Risks:

technical risks are also hard to foresee and may be underestimated.

Lack of Precedents and Comparables:

- Absence of transaction evidence, industry standards or regulatory clarity for valuation

benchmarks regarding technologies, procedures or business models at the frontier of what is

Ethical and Legal Risks:

- Effects of laws, regulator actions, shifts in social acceptance levels on probability of success

assumptions are extremely hard to reliably forecast for ventures/experimentation operating in

legal/ethical grey areas.

Information Asymmetry:

- Limited disclosure of detailed methodologies, data and outcome metrics by private

biohacking outfits further hinders independent verification/scrutiny of reported values and

assumptions by financial statement users.

considerable measurement subjectivity, uncertainties and audit risks. Conservative

Some practical guidelines for accounting for equity investments in speculative biohacking

ventures include:

Classification:

- Generally treat as investments in associates if significant influence exists per IAS 28, else as

equity instruments at fair value through profit or loss under IFRS 9/FASB 321 given lack of

control.

- Record investments at transaction price which approximates fair value given seed-round

characteristics absent active markets.

Subsequent Measurement:

- Compare carrying amount to value in use estimated using DCF of projected cash flows.

- Provide robust explanations of judgements, valuation methodologies applied, assumptions

used and their inherent limitations/sensitivities due to early stage nature.

The objective is to apply principles of neutrality, prudence and transparency given limitations

of numerical valuations for high-risk investments lacking precedents or reliable forecasts.

Comparative treatment year-over-year is also important for financial analysis.

Conclusion

Accounting for investments in biohacking ventures and human modification experimentation

presents challenges due to technologies being at the outer frontiers of what is scientifically

known and legally/ethically permissible. Existing accounting frameworks provide little

exposure to emerging opportunities.

apply numerical valuations to high-risk sci-tech endeavors lacking data benchmarks.

Independent verification is also difficult given information asymmetries.

As the fields of biotechnology, genetics, synthetic biology, brain-computer interfaces, human

commercial viability and ethical/regulatory acceptance levels, more precedents will emerge

enabling the development of more definitive accounting principles. For now, prudent

conservatism and transparency are advisable when dealing with the financial reporting of

speculative ventures at the frontier of science, law and ethics.

Biohacking refers to the controversial practice of conducting experiments on one's own body

in an attempt to enhance or augment human abilities and functions. This includes implanting

technology under the skin or modifying DNA, nerve cells and tissues at a microscopic level.

experimental nature of the science as well as ethical and legal uncertainties. This paper will

perspective.

Biohacking Business Models and Investments

There are a few common models emerging where for-profit capital is being allocated towards

biohacking-enabling goals:

- Biotechnology startups conducting R&D into areas like nootropics, brain-computer

interfaces, genetic engineering and synthetic biology for potential medical or enhancement

applications. Early investment goes towards lab equipment, prototype development and

clinical trials.

- Wearable device/app companies developing products allowing tracking and optimization of

bodily metrics like sleep, activity levels, brainwaves etc. Many also explore closed-loop

systems offering real-time biofeedback. Seed funding supports software/hardware

engineering.

open-source projects in fields such as regenerative medicine, genetic engineering and

facing regulatory risks.

- Peer-to-peer investment platforms allow individuals to crowdfund or invest in projects

focused on anti-aging, nootropic formulations, brain computer interfaces and other biohack-

The dilemma for investors and accountants lies in dealing with the high uncertainty and low

probabilities of success characteristic of cutting-edge science, presence of unproven concepts

rather than productized innovations and ethical/legal risks associated with human bodily

Accounting Recognition and Measurement

There is little authoritative accounting guidance covering investments in speculative frontier

Research and Development Costs

standards.

- Costs contributing to identifiable assets meeting capitalization criteria could potentially be

recognized as intangible development assets if technical/commercial feasibility can be

reasonably demonstrated. High threshold given uncertainties.

- Investments in biohacking startups taking form of preferred shares or common stock would

likely be classified as investments in associates (IAS 28) or equity securities (FASB 321)

depending on level of influence.

- Recognition is at fair value with changes through profit and loss unless ownership level

allows use of equity method reporting share of associate net assets/profits. Valuation is highly

subjective given early stage.

Body Modification Procedures

medical practice.

Impairment Testing

- For recognized intangibles and equity investments, significant doubt exists over ability to

generate sufficient cash flows to recover carrying amounts due to technology/market risks.

- Impairment assessments require highly subjective assumptions for determining recoverable

amounts using value-in-use or fair value less costs of disposal methods. Sensitivities should

be disclosed.

- Thorough qualitative disclosures on judgements applied, uncertainties, risk factors and

sensitivity of measurements to assumptions is critical given volatility and lack of precedents

in financial reporting of biohacking endeavors.

Accounting Challenges in Biohacking Investments

Long Development Cycles:

scientific, regulatory and ethical hurdles. This increases uncertainty in cash flow projections

for impairment tests and asset valuations.

- Delineating research costs from identifiable intangible development assets meeting

capitalization criteria is difficult due to blurred lines between investigation and applied

development phases when technologies are radical and unproven.

Ever-Changing Goals and Risks:

- Objectives of biohacking projects can shift substantially over time in response to R&D

results or emerging opportunities, increasing measurement subjectivity. Technical and non-

technical risks are also hard to foresee and may be underestimated.

benchmarks regarding technologies, procedures or business models at the frontier of what is

assumptions are extremely hard to reliably forecast for ventures/experimentation operating in

legal/ethical grey areas.

Information Asymmetry:

biohacking outfits further hinders independent verification/scrutiny of reported values and

assumptions by financial statement users.

While applying standard accounting frameworks, the above complexities introduce

approaches and robust disclosure are advisable in circumstances lacking precedents and

controls.

Accounting for Equity Investments in Biohacking

control.

Initial Recognition:

- Record investments at transaction price which approximates fair value given seed-round

characteristics absent active markets.

The dilemma for investors and accountants lies in dealing with the high uncertainty and low

probabilities of success characteristic of cutting-edge science, presence of unproven concepts

rather than productized innovations and ethical/legal risks associated with human bodily

experimentation.

Accounting Recognition and Measurement

There is little authoritative accounting guidance covering investments in speculative frontier

sci-tech ventures or human experimentation. Judgement is required to determine appropriate

- Costs contributing to identifiable assets meeting capitalization criteria could potentially be

recognized as intangible development assets if technical/commercial feasibility can be

reasonably demonstrated. High threshold given uncertainties.

Equity Instruments

- Investments in biohacking startups taking form of preferred shares or common stock would

likely be classified as investments in associates (IAS 28) or equity securities (FASB 321)

depending on level of influence.

- Recognition is at fair value with changes through profit and loss unless ownership level

allows use of equity method reporting share of associate net assets/profits. Valuation is highly

subjective given early stage.

evidence procedures satisfy local laws/ethics standards.

Impairment Testing

- For recognized intangibles and equity investments, significant doubt exists over ability to

generate sufficient cash flows to recover carrying amounts due to technology/market risks.

- Impairment assessments require highly subjective assumptions for determining recoverable

amounts using value-in-use or fair value less costs of disposal methods. Sensitivities should

be disclosed.

Disclosure Requirements

- Thorough qualitative disclosures on judgements applied, uncertainties, risk factors and

sensitivity of measurements to assumptions is critical given volatility and lack of precedents

in financial reporting of biohacking endeavors.

experimentation from an accounting perspective. Significant subjectivity is inevitable.

Long Development Cycles:

- Timelines to progress concepts/inventions to marketability are extended due to complex

scientific, regulatory and ethical hurdles. This increases uncertainty in cash flow projections

for impairment tests and asset valuations.

Intangible Asset Identification:

- Delineating research costs from identifiable intangible development assets meeting

capitalization criteria is difficult due to blurred lines between investigation and applied

development phases when technologies are radical and unproven.

Ever-Changing Goals and Risks:

- Objectives of biohacking projects can shift substantially over time in response to R&D

results or emerging opportunities, increasing measurement subjectivity. Technical and non-

technical risks are also hard to foresee and may be underestimated.

scientifically/legally possible.

- Effects of laws, regulator actions, shifts in social acceptance levels on probability of success

legal/ethical grey areas.

Information Asymmetry:

- Limited disclosure of detailed methodologies, data and outcome metrics by private

biohacking outfits further hinders independent verification/scrutiny of reported values and

assumptions by financial statement users.

While applying standard accounting frameworks, the above complexities introduce

considerable measurement subjectivity, uncertainties and audit risks. Conservative

approaches and robust disclosure are advisable in circumstances lacking precedents and

controls.

ventures include:

equity instruments at fair value through profit or loss under IFRS 9/FASB 321 given lack of

control.

Initial Recognition:

characteristics absent active markets.

Subsequent Measurement:

- Use basic valuation techniques like option pricing or recent transaction benchmarks with

Impairment Testing:

- Compare carrying amount to value in use estimated using DCF of projected cash flows.

Incorporate high discount rates and scenario analysis reflecting technology and market

used and their inherent limitations/sensitivities due to early stage nature.

of numerical valuations for high-risk investments lacking precedents or reliable forecasts.

Conclusion

known and legally/ethically permissible. Existing accounting frameworks provide little

definitive guidance requiring management to apply careful judgement. However, failure to

recognize such activities could misrepresent an entity's financial position and economic

exposure to emerging opportunities.

This paper has proposed high-level frameworks for classifying costs, recognizing and

measuring investments in biohacking according to basic IFRS/GAAP concepts. It emphasizes

robust qualitative disclosure to convey substantial uncertainties inherent in attempting to

apply numerical valuations to high-risk sci-tech endeavors lacking data benchmarks.

As the fields of biotechnology, genetics, synthetic biology, brain-computer interfaces, human

speculative ventures at the frontier of science, law and ethics.

Biohacking refers to the controversial practice of conducting experiments on one's own body

technology under the skin or modifying DNA, nerve cells and tissues at a microscopic level.

While still in its infancy, interest in biohacking is growing among some scientists,

entrepreneurs and ordinary people seeking "self-improvement." This has spurred investment

from venture capital funds looking to tap into emerging biotechnology opportunities.

experimental nature of the science as well as ethical and legal uncertainties. This paper will

examine the issues surrounding the appropriate financial reporting of money invested in

biohacking-related ventures, research and body modification procedures from an accounting

perspective.

applications. Early investment goes towards lab equipment, prototype development and

- Wearable device/app companies developing products allowing tracking and optimization of

bodily metrics like sleep, activity levels, brainwaves etc. Many also explore closed-loop

- DIY bio labs and "bioart collectives" where member subscriptions and donations finance

open-source projects in fields such as regenerative medicine, genetic engineering and

microbiome modification. Goals are knowledge sharing rather than commercialization.

- Underground body modification facilities performing procedures like microchipping,

magnet implants and augmented reality contact lenses for a fee. Operate in legal grey areas

facing regulatory risks.

enabling inventions and scientific pursuits.

experimentation.

Accounting Recognition and Measurement

sci-tech ventures or human experimentation. Judgement is required to determine appropriate

classification, timing of recognition and measurement approaches. Some considerations

include:

- Expenses incurred towards open-ended investigation of concepts and ideas without definite

commercial potential would qualify as research costs expensed under IAS 38 and FASB

standards.

Equity Instruments

depending on level of influence.

- Recognition is at fair value with changes through profit and loss unless ownership level

allows use of equity method reporting share of associate net assets/profits. Valuation is highly

subjective given early stage.

- Payments towards human experimentation procedures pose complex measurement issues.

Recording as intangible assets on balance sheet could constitute endorsement of unregulated

medical practice.

- Treatment as R&D or general marketing/sales costs may be most reasonable classification

absent assets arising despite outcomes highly uncertain. Any asset recognition requires

evidence procedures satisfy local laws/ethics standards.

Impairment Testing

Disclosure Requirements

- Thorough qualitative disclosures on judgements applied, uncertainties, risk factors and

sensitivity of measurements to assumptions is critical given volatility and lack of precedents

in financial reporting of biohacking endeavors.

The proposed framework aims to balance principles of faithful representation while

highlighting limitations of numerical values attributed to such frontier ventures and human

experimentation from an accounting perspective. Significant subjectivity is inevitable.

Some special challenges in reporting on biohacking ventures include:

Long Development Cycles:

- Timelines to progress concepts/inventions to marketability are extended due to complex

- Delineating research costs from identifiable intangible development assets meeting

- Objectives of biohacking projects can shift substantially over time in response to R&D

results or emerging opportunities, increasing measurement subjectivity. Technical and non-

technical risks are also hard to foresee and may be underestimated.

- Absence of transaction evidence, industry standards or regulatory clarity for valuation

benchmarks regarding technologies, procedures or business models at the frontier of what is

scientifically/legally possible.

Ethical and Legal Risks:

- Effects of laws, regulator actions, shifts in social acceptance levels on probability of success

assumptions are extremely hard to reliably forecast for ventures/experimentation operating in

legal/ethical grey areas.

biohacking outfits further hinders independent verification/scrutiny of reported values and

approaches and robust disclosure are advisable in circumstances lacking precedents and

controls.

Accounting for Equity Investments in Biohacking

ventures include:

Classification:

equity instruments at fair value through profit or loss under IFRS 9/FASB 321 given lack of

control.

Initial Recognition:

- Use basic valuation techniques like option pricing or recent transaction benchmarks with

Impairment Testing:

Incorporate high discount rates and scenario analysis reflecting technology and market

development uncertainty.

- Provide robust explanations of judgements, valuation methodologies applied, assumptions

used and their inherent limitations/sensitivities due to early stage nature.

The objective is to apply principles of neutrality, prudence and transparency given limitations

of numerical valuations for high-risk investments lacking precedents or reliable forecasts.

Comparative treatment year-over-year is also important for financial analysis.

Conclusion

known and legally/ethically permissible. Existing accounting frameworks provide little

This paper has proposed high-level frameworks for classifying costs, recognizing and

measuring investments in biohacking according to basic IFRS/GAAP concepts. It emphasizes

robust qualitative disclosure to convey substantial uncertainties inherent in attempting to

apply numerical valuations to high-risk sci-tech endeavors lacking data benchmarks.

As the fields of biotechnology, genetics, synthetic biology, brain-computer interfaces, human

augmentation and regenerative medicine progress over time in terms of scientific milestones,

commercial viability and ethical/regulatory acceptance levels, more precedents will emerge

conservatism and transparency are advisable when dealing with the financial reporting of

speculative ventures at the frontier of science, law and ethics.

entrepreneurs and ordinary people seeking "self-improvement." This has spurred investment

experimental nature of the science as well as ethical and legal uncertainties. This paper will

biohacking-related ventures, research and body modification procedures from an accounting

perspective.

There are a few common models emerging where for-profit capital is being allocated towards

biohacking-enabling goals:

- Biotechnology startups conducting R&D into areas like nootropics, brain-computer

interfaces, genetic engineering and synthetic biology for potential medical or enhancement

applications. Early investment goes towards lab equipment, prototype development and

clinical trials.

- Wearable device/app companies developing products allowing tracking and optimization of

engineering.

- Underground body modification facilities performing procedures like microchipping,

magnet implants and augmented reality contact lenses for a fee. Operate in legal grey areas

facing regulatory risks.

- Peer-to-peer investment platforms allow individuals to crowdfund or invest in projects

focused on anti-aging, nootropic formulations, brain computer interfaces and other biohack-

enabling inventions and scientific pursuits.

probabilities of success characteristic of cutting-edge science, presence of unproven concepts

rather than productized innovations and ethical/legal risks associated with human bodily

experimentation.

classification, timing of recognition and measurement approaches. Some considerations

Research and Development Costs

commercial potential would qualify as research costs expensed under IAS 38 and FASB

standards.

- Costs contributing to identifiable assets meeting capitalization criteria could potentially be

recognized as intangible development assets if technical/commercial feasibility can be

reasonably demonstrated. High threshold given uncertainties.

Equity Instruments

- Investments in biohacking startups taking form of preferred shares or common stock would

likely be classified as investments in associates (IAS 28) or equity securities (FASB 321)

depending on level of influence.

subjective given early stage.

medical practice.

- Treatment as R&D or general marketing/sales costs may be most reasonable classification

absent assets arising despite outcomes highly uncertain. Any asset recognition requires

Impairment Testing

- For recognized intangibles and equity investments, significant doubt exists over ability to

generate sufficient cash flows to recover carrying amounts due to technology/market risks.

- Impairment assessments require highly subjective assumptions for determining recoverable

amounts using value-in-use or fair value less costs of disposal methods. Sensitivities should

be disclosed.

experimentation from an accounting perspective. Significant subjectivity is inevitable.

Accounting Challenges in Biohacking Investments

Some special challenges in reporting on biohacking ventures include:

This paper has proposed high-level frameworks for classifying costs, recognizing and

measuring investments in biohacking according to basic IFRS/GAAP concepts. It emphasizes

robust qualitative disclosure to convey substantial uncertainties inherent in attempting to

apply numerical valuations to high-risk sci-tech endeavors lacking data benchmarks.

Independent verification is also difficult given information asymmetries.

As the fields of biotechnology, genetics, synthetic biology, brain-computer interfaces, human

augmentation and regenerative medicine progress over time in terms of scientific milestones,

commercial viability and ethical/regulatory acceptance levels, more precedents will emerge

speculative ventures at the frontier of science, law and ethics.

technology under the skin or modifying DNA, nerve cells and tissues at a microscopic level.

While still in its infancy, interest in biohacking is growing among some scientists,

entrepreneurs and ordinary people seeking "self-improvement." This has spurred investment

from venture capital funds looking to tap into emerging biotechnology opportunities.

experimental nature of the science as well as ethical and legal uncertainties. This paper will

examine the issues surrounding the appropriate financial reporting of money invested in

biohacking-related ventures, research and body modification procedures from an accounting

perspective.

Biohacking Business Models and Investments

There are a few common models emerging where for-profit capital is being allocated towards

biohacking-enabling goals:

systems offering real-time biofeedback. Seed funding supports software/hardware

- DIY bio labs and "bioart collectives" where member subscriptions and donations finance

open-source projects in fields such as regenerative medicine, genetic engineering and

- Underground body modification facilities performing procedures like microchipping,

magnet implants and augmented reality contact lenses for a fee. Operate in legal grey areas

facing regulatory risks.

- Peer-to-peer investment platforms allow individuals to crowdfund or invest in projects

focused on anti-aging, nootropic formulations, brain computer interfaces and other biohack-

enabling inventions and scientific pursuits.

The dilemma for investors and accountants lies in dealing with the high uncertainty and low

experimentation.

sci-tech ventures or human experimentation. Judgement is required to determine appropriate

classification, timing of recognition and measurement approaches. Some considerations

include:

- Expenses incurred towards open-ended investigation of concepts and ideas without definite

commercial potential would qualify as research costs expensed under IAS 38 and FASB

standards.

recognized as intangible development assets if technical/commercial feasibility can be

reasonably demonstrated. High threshold given uncertainties.

Equity Instruments

- Recognition is at fair value with changes through profit and loss unless ownership level

- Payments towards human experimentation procedures pose complex measurement issues.

Recording as intangible assets on balance sheet could constitute endorsement of unregulated

medical practice.

- Treatment as R&D or general marketing/sales costs may be most reasonable classification

absent assets arising despite outcomes highly uncertain. Any asset recognition requires

evidence procedures satisfy local laws/ethics standards.

Impairment Testing

- For recognized intangibles and equity investments, significant doubt exists over ability to

generate sufficient cash flows to recover carrying amounts due to technology/market risks.

- Impairment assessments require highly subjective assumptions for determining recoverable

The proposed framework aims to balance principles of faithful representation while

highlighting limitations of numerical values attributed to such frontier ventures and human

experimentation from an accounting perspective. Significant subjectivity is inevitable.

Accounting Challenges in Biohacking Investments

Some special challenges in reporting on biohacking ventures include:

Long Development Cycles:

scientific, regulatory and ethical hurdles. This increases uncertainty in cash flow projections

for impairment tests and asset valuations.

Intangible Asset Identification:

Ever-Changing Goals and Risks:

technical risks are also hard to foresee and may be underestimated.

Lack of Precedents and Comparables:

- Absence of transaction evidence, industry standards or regulatory clarity for valuation

benchmarks regarding technologies, procedures or business models at the frontier of what is

Ethical and Legal Risks:

- Effects of laws, regulator actions, shifts in social acceptance levels on probability of success

assumptions are extremely hard to reliably forecast for ventures/experimentation operating in

legal/ethical grey areas.

Information Asymmetry:

- Limited disclosure of detailed methodologies, data and outcome metrics by private

biohacking outfits further hinders independent verification/scrutiny of reported values and

assumptions by financial statement users.

considerable measurement subjectivity, uncertainties and audit risks. Conservative

Some practical guidelines for accounting for equity investments in speculative biohacking

ventures include:

Classification:

- Generally treat as investments in associates if significant influence exists per IAS 28, else as

equity instruments at fair value through profit or loss under IFRS 9/FASB 321 given lack of

control.

- Record investments at transaction price which approximates fair value given seed-round

characteristics absent active markets.

Subsequent Measurement:

- Compare carrying amount to value in use estimated using DCF of projected cash flows.

- Provide robust explanations of judgements, valuation methodologies applied, assumptions

used and their inherent limitations/sensitivities due to early stage nature.

The objective is to apply principles of neutrality, prudence and transparency given limitations

of numerical valuations for high-risk investments lacking precedents or reliable forecasts.

Comparative treatment year-over-year is also important for financial analysis.

Conclusion

Accounting for investments in biohacking ventures and human modification experimentation

presents challenges due to technologies being at the outer frontiers of what is scientifically

known and legally/ethically permissible. Existing accounting frameworks provide little

exposure to emerging opportunities.

apply numerical valuations to high-risk sci-tech endeavors lacking data benchmarks.

Independent verification is also difficult given information asymmetries.

As the fields of biotechnology, genetics, synthetic biology, brain-computer interfaces, human

commercial viability and ethical/regulatory acceptance levels, more precedents will emerge

enabling the development of more definitive accounting principles. For now, prudent

conservatism and transparency are advisable when dealing with the financial reporting of

speculative ventures at the frontier of science, law and ethics.

Biohacking refers to the controversial practice of conducting experiments on one's own body

in an attempt to enhance or augment human abilities and functions. This includes implanting

technology under the skin or modifying DNA, nerve cells and tissues at a microscopic level.

experimental nature of the science as well as ethical and legal uncertainties. This paper will

perspective.

Biohacking Business Models and Investments

There are a few common models emerging where for-profit capital is being allocated towards

biohacking-enabling goals:

- Biotechnology startups conducting R&D into areas like nootropics, brain-computer

interfaces, genetic engineering and synthetic biology for potential medical or enhancement

applications. Early investment goes towards lab equipment, prototype development and

clinical trials.

- Wearable device/app companies developing products allowing tracking and optimization of

bodily metrics like sleep, activity levels, brainwaves etc. Many also explore closed-loop

systems offering real-time biofeedback. Seed funding supports software/hardware

engineering.

open-source projects in fields such as regenerative medicine, genetic engineering and

facing regulatory risks.

- Peer-to-peer investment platforms allow individuals to crowdfund or invest in projects

focused on anti-aging, nootropic formulations, brain computer interfaces and other biohack-

The dilemma for investors and accountants lies in dealing with the high uncertainty and low

probabilities of success characteristic of cutting-edge science, presence of unproven concepts

rather than productized innovations and ethical/legal risks associated with human bodily

Accounting Recognition and Measurement

There is little authoritative accounting guidance covering investments in speculative frontier

Research and Development Costs

standards.

- Costs contributing to identifiable assets meeting capitalization criteria could potentially be

recognized as intangible development assets if technical/commercial feasibility can be

reasonably demonstrated. High threshold given uncertainties.

- Investments in biohacking startups taking form of preferred shares or common stock would

likely be classified as investments in associates (IAS 28) or equity securities (FASB 321)

depending on level of influence.

- Recognition is at fair value with changes through profit and loss unless ownership level

allows use of equity method reporting share of associate net assets/profits. Valuation is highly

subjective given early stage.

Body Modification Procedures

medical practice.

Impairment Testing

- For recognized intangibles and equity investments, significant doubt exists over ability to

generate sufficient cash flows to recover carrying amounts due to technology/market risks.

- Impairment assessments require highly subjective assumptions for determining recoverable

amounts using value-in-use or fair value less costs of disposal methods. Sensitivities should

be disclosed.

- Thorough qualitative disclosures on judgements applied, uncertainties, risk factors and

sensitivity of measurements to assumptions is critical given volatility and lack of precedents

in financial reporting of biohacking endeavors.

Accounting Challenges in Biohacking Investments

Long Development Cycles:

scientific, regulatory and ethical hurdles. This increases uncertainty in cash flow projections

for impairment tests and asset valuations.

- Delineating research costs from identifiable intangible development assets meeting

capitalization criteria is difficult due to blurred lines between investigation and applied

development phases when technologies are radical and unproven.

Ever-Changing Goals and Risks:

- Objectives of biohacking projects can shift substantially over time in response to R&D

results or emerging opportunities, increasing measurement subjectivity. Technical and non-

technical risks are also hard to foresee and may be underestimated.

benchmarks regarding technologies, procedures or business models at the frontier of what is

assumptions are extremely hard to reliably forecast for ventures/experimentation operating in

legal/ethical grey areas.

Information Asymmetry:

biohacking outfits further hinders independent verification/scrutiny of reported values and

assumptions by financial statement users.

While applying standard accounting frameworks, the above complexities introduce

approaches and robust disclosure are advisable in circumstances lacking precedents and

controls.

Accounting for Equity Investments in Biohacking

control.

Initial Recognition:

- Record investments at transaction price which approximates fair value given seed-round

characteristics absent active markets.

- Use basic valuation techniques like option pricing or recent transaction benchmarks with

suitable discounting for lack of comparables/liquidity.

Impairment Testing:

- Compare carrying amount to value in use estimated using DCF of projected cash flows.

Incorporate high discount rates and scenario analysis reflecting technology and market

development uncertainty.

Disclosures:

Conclusion

Accounting for investments in biohacking ventures and human modification experimentation

presents challenges due to technologies being at the outer frontiers of what is scientifically

definitive guidance requiring management to apply careful judgement. However, failure to

recognize such activities could misrepresent an entity's financial position and economic

exposure to emerging opportunities.

measuring investments in biohacking according to basic IFRS/GAAP concepts. It emphasizes

robust qualitative disclosure to convey substantial uncertainties inherent in attempting to

apply numerical valuations to high-risk sci-tech endeavors lacking data benchmarks.

Independent verification is also difficult given information asymmetries.

enabling the development of more definitive accounting principles. For now, prudent